FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression

19/05/2020 MaP Cancer, FDA 0

Food and Drug Administration approved atezolizumab (TECENTRIQ®, Genentech Inc.) for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), with no EGFR or ALK genomic tumor aberrations.

More information here


https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-atezolizumab-first-line-treatment-metastatic-nsclc-high-pd-l1-expression?utm_campaign=Oncology%205-18-2020%20atezolizumab&utm_medium=email&utm_source=Eloqua

  • FDA-